hypolipidemic property
Recently Published Documents


TOTAL DOCUMENTS

6
(FIVE YEARS 1)

H-INDEX

3
(FIVE YEARS 0)

2021 ◽  
Vol 4 (1) ◽  
pp. 01-03
Author(s):  
Irina V Okunevich

The short clinical study is devoted to the corrective action of the neurotropic drug LEVOPA (L-DOPA) in patients with coronary artery disease (CAD) complicated by atherogenic dyslipidemia (DLP), moderate angina pectoris (AP), arterial hypertension (AH) and other risk factors for the development of atherosclerosis (AS). Purposefully in neurology, drug of L-DOPA - LEVOPA is used in significant doses (3-10 g/day) to treat Parkinson's disease, including atherosclerotic genesis. In this study, the neurotropic drug LEVOPA was used as an active metabolic agent in the complex therapy of CAD in a small dose of 0.5 g 3 times a day, with chronic oral administration for 4 weeks. As a result, an improvement in the lipid profile of blood and the hypolipidemic property of the drug LEVOPA were found. An improvement in hemodynamics and general well-being was noted in treated patients with aggravating risk factors for the development of AS. We had notice the decrease of lipid peroxidation (LPO) too.


Author(s):  
Rajesh Kumar Suman ◽  
Ipseeta Ray Mohanty ◽  
Manjusha K. Borde ◽  
Y. A. Deshmukh ◽  
Anurag Pathak ◽  
...  

Background: The medicinal plant Murraya koenigii shown to have a wide variety of pharmacological activities (hypoglycemic and hypolipidemic). Objective of this study is the present study was designed to evaluate Antidiabetic and Hypolipidemic property of Murraya koenigii in experimentally induced diabetes in rats.Methods: Experimental diabetes was produced with single dose of Streptozotocin (STZ): 45 mg/kg IP. The rats were randomly allocated in various groups for 37 days. After the confirmation of diabetes on 7th day (>200 mg/dl), hydroalcoholic extract of Murraya koenigii (500 mg/kg) was administered orally to experimental rats from day 7th day and continued for 37 days thereafter. Various antidiabetic (Glucose, HbA1C), metabolic (Lipid profile), safety (pancreatic lipase, Creatinine, SGPT, Histopathology of Liver and Kidney) were evaluated in various group.Results: Efficacy of Murraya koenigii was observed on various parameter of diabetes. Administration of STZ resulted in a significant decrease in diabetic changes (increase in blood glucose, HbA1C), altered lipid profile (p<0.01) in the Control group rats as compared to sham group. Murraya koenigii treatment demonstrated significant antidiabetic indicated by restoration of blood glucose, HbA1C level (p<0.01) compared to Control group. In addition, Murraya koenigii also documented hypolipidemic property of test drug. As per biochemical assessment of Pancreatic lipase, Serum creatinine, SGPT and Histopathological report, the test drug reduce the pancreatic, liver and renal marker and also showed safe to pancreas, Liver and kidney. The histopathological assessment of the liver and kidney confirmed the biochemical findings.Conclusions: The study concluded that the Murraya koenigii possess antidiabetic efficacy.


2015 ◽  
Vol 21 (1) ◽  
pp. 77-86 ◽  
Author(s):  
Hisayuki Nakayama ◽  
Naho Yuito ◽  
Yuji Miyata ◽  
Kei Tamaya ◽  
Takashi Tanaka ◽  
...  

1973 ◽  
Vol 26 (11) ◽  
pp. 681-686 ◽  
Author(s):  
MIKIO SAWADA ◽  
TOMOYOSHI HOSOKAWA ◽  
TSUNEO OKUTOMI ◽  
KUNIO ANDO

Sign in / Sign up

Export Citation Format

Share Document